AR056875A1 - Ligandos del receptor vaniloide y su aplicacion para la fabricacion de medicamentos - Google Patents
Ligandos del receptor vaniloide y su aplicacion para la fabricacion de medicamentosInfo
- Publication number
- AR056875A1 AR056875A1 ARP060104575A ARP060104575A AR056875A1 AR 056875 A1 AR056875 A1 AR 056875A1 AR P060104575 A ARP060104575 A AR P060104575A AR P060104575 A ARP060104575 A AR P060104575A AR 056875 A1 AR056875 A1 AR 056875A1
- Authority
- AR
- Argentina
- Prior art keywords
- unsubstituted
- monosubstituted
- saturated
- radical
- unsaturated
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 25
- 150000003254 radicals Chemical class 0.000 abstract 16
- -1 aliphatic radical Chemical class 0.000 abstract 14
- 229910052757 nitrogen Inorganic materials 0.000 abstract 10
- 125000002950 monocyclic group Chemical group 0.000 abstract 8
- 125000005842 heteroatom Chemical group 0.000 abstract 6
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 2
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 abstract 2
- 125000004419 alkynylene group Chemical group 0.000 abstract 2
- 125000004474 heteroalkylene group Chemical group 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 101150024084 nhr-28 gene Proteins 0.000 abstract 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 150000005840 aryl radicals Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/83—Thioacids; Thioesters; Thioamides; Thioimides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/02—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
Abstract
Reivindicacion 1: Compuestos sustituidos de la formula general (1), en la que X representa O, S o N-CsN; Y representa -NH2, -NHR30, -NR31R32 o representa un radical alifático C1-10 lineal o ramificado, saturado o insaturado, no sustituido o al menos monosustituido; n representa 0, 1, 2, 3 o 4; R1, R2, R3 y R4, independientemente entre sí, cada uno representa H; F; CI; Br; I; -SF5; -NO2; -CF3; -CN; -NH2; -OH; -SH; -C(=O)-NH2; -S(=O)2-NH2; C(=O)-NH-OH;-C(=O)-OH; -C(=O)-H; -S(=O)2-OH; -NHR11; - NR12R13; -OR14; -SR15; -C(=O)-NHR16; -C(=O)-NR17R18; -S(=O)2NHR19; -S(=O)2-NR20R21; - C(=O)-OR22; -C(=O)-R23; -S(=O)-R24; -S(=O)2R24 o representan un radical alifático C1-10 lineal o ramificado, saturado o insaturado, no sustituido o al menos monosustituido; R5 representa H; F; CI; Br; I; -SF5; -NO2; -CF3; -CF2CI; -CN; -NH2; -OH; -SH; -C(=O)-NH2; -S(=O)2-NH2; -C(=O)-NH-OH; -C(=O)-OH; -C(=O)-H; -S(=O)2-OH; -NHR11; -NR12R13; -OR14; -SR15; -C(=O)-NHR16; -C(=O)NR17R18; -S(=O)2-NHR19; -S(=O)2- NR20R21; -C(=O)-OR22; C(=O)R23, -S(=O)2-R24; -S(=O)-R24; representa un radical alifático C1-10 lineal o ramificado, saturado o insaturado, no sustituido o al menos monosustituido; o representa un radical cicloalifático de 3, 4, 5, 6, 7, 8, o 9 miembros insaturado o saturado, no sustituido o al menos monosustituido opcionalmente comprendiendo al menos un heteroátomo como miembro del anillo, en lo cual el radical se enlaza en cada caso a la estructura original mediante un átomo de carbono en el anillo del radical cicloalifático; T representa C-R6 y U representa C-R7 y V representa N y W representa C-R8 o T representa C-R6 y U representa N y V representa C-R9 y W representa C-R8 o T representa N y U representa C-R7 y V representa C-R9 y W representa C-R8 o T representa N y U representa N y V representa C-R9 y W representa C-R8 o T representa N y U representa C-R7 y V representa N y W representa C-R8 o T representa C-R6 y U representa N y V representa N y W representa C-R8 o T representa C-R6 y U representa C-R7 y V representa C-R9 y W representa C-R10; R6 y R7, independientemente entre sí, cada uno representa H; F; CI; Br; I; -SF5; -NO2; -CF3; -CF2CI; -CN; -NH2; -OH; -SH; -C(=O)-NH2; -S(=O)2-NH2; -C(=O)-NH-OH; -C(=O)-OH; -C(=O)-H; -S(=O)2-OH; -NHR11; -NR12R13; -OR14; -SR15; -C(=O)-NHR16; -C(=O)-NR17R18; -S(=O)2-NHR19; -S(=O)2-NR20R21; -C(=O)-OR22; -C(=O)-R23, -S(=O)-R24; -S(=O)2-R24; representan un radical alifático C1-10 lineal o ramificado, saturado o insaturado, no sustituido o al menos monosustituido; o representan un radical arilo de 6 o 10 miembros no sustituido o al menos monosustituido, la cual se puede enlazar por un grupo alquileno C1-6 o un grupo alquenileno C2-6 o un grupo alquinileno C2-6 lineal o ramificado, no sustituido o al menos monosustituido; R8 representa H; F; CI; Br; I; -SF5; -NO2; -CF3; -CF2CI; -CN; -NH2; -OH; -SH; -C(=O)-NH2; -S(=O)2-NH2; -C(=O)-NH-OH; -C(=O)-OH; -C(=O)-H; -S(=O)2-OH; -NHR11; -NR12R13; -OR14; -SR15; -C(=O)-NHR16; - C(=O)-NR17R18; -S(=O)2-NHR19; -S(=O)2-NR20R21; -C(=O)-OR22; -C(=O)-R23; -S(=O)-R24 -S(=O)2-R24; -C(=NH)-NH2; -C(=NH)-NH-R27; -N=C(NH2)2; -N=C(NHR28)(NHR29); representa un radical alifático C1-10 lineal o ramificado, saturado o insaturado, no sustituido o al menos monosustituido; representa un radical cicloalifático de 3, 4, 5, 6, 7, 8, o 9 miembros insaturado o saturado, no sustituido o al menos monosustituido, que presenta opcionalmente al menos un heteroátomo como miembro del anillo, en lo cual el radical se enlaza en cada caso a la estructura original mediante un átomo de carbono en el anillo del radical cicloalifático y que puede estar fusionado con un sistema cíclico mono- o policíclico saturado o insaturado, no sustituido o al menos monosustituido y/o se puede enlazar por un grupo alquileno C1-6- o grupo alquenileno C2-6- o un grupo alquinileno C2-6- lineal o ramificado, no sustituido o al menos monosustituido; o representa un radical arilo o heteroarilo de 5 a 14 miembros no sustituido o al menos monosustituido, que puede estar fusionado con un sistema cíclico mono- o policíclico saturado o insaturado, no sustituido o al menos monosustituido y/o se puede enlazar por un grupo alquileno C1-6- o un grupo alquenileno C2-6- o un grupo alquinileno C2-6- lineal o ramificado, no sustituido o al menos monosustituido; R9 representa H; F; CI; Br; I; -SF5; -NO2; -CF3; -CF2CI; -CN; -NH2; -OH; - SH; -C(=O)-NH2; -S(=O)2-NH2; -C(=O)-NH-OH; -C(=O)-OH; -C(=O)-H; - S(=O)2-OH; -NHR11; -NR12R13; -OR14; -SR15; -C(=O)-NHR16; -C(=O)NR17R18; -S(=O)rNHR19; -S(=O)2-NR20R21; -C(=O)-OR22; -C(=O)-R23; -S(=O)-R24; -S(=O)2-R24 o representa un radical alifático C1-10 lineal o ramificado, saturado o insaturado, no sustituido o al menos monosustituido; R10 representa -SF5; -NO2; -CF3; -CF2CI; -CN; -NH2; -OH; -SH; -C(=O)-NH2; -S(=O)2-NH2; -C(=O)-NH-OH; -C(=O)-OH; -C(=O)-H; -S(=O)2-OH; -NHR11; -NR12R13; -OR14; -SR15; -C(=O)-NHR16; -C(=O)-NR17R18; -S(=O)2-NHR19; -S(=O)2- NR20R21; -C(=O)-OR22; -C(=O)-R23; -S(=O)-R24; -S(=O)2-R24; -C(=NH)-NH2; -C(=NH)-NH-R27; -N=C(NH2)2; -N=C(NHR28)(NHR29); representa un radical alifático C1-10 lineal o ramificado, saturado o insaturado, que está en cada caso sustituido con opcionalmente 1, 2, 3, 4, 5, 6, 7, 8 o 9 sustituyentes mutuamente independientemente seleccionados del grupo que consiste en -CN, -NO2, -OH, -NH2, -SH, -O(alquilo C1-5), -S(alquilo C1-5), -NH(alquilo C1-5), -N(alquilo C1-5)(alquilo C1-5),-OCF3 y - SCF3; representa un radical no sustituido alquenilo C2-10 o un radical no sustituido alquinilo C2-10; representa un radical cicloalifático de 3-, 4-, 5-, 6-, 7-, 8- o 9 miembros insaturado o saturado, no sustituido o al menos monosustituido, opcionalmente comprendiendo al menos un heteroátomo como miembro del anillo, en lo cual el radical se enlaza en cada caso a la estructura original mediante un átomo de carbono en el anillo del radical cicloalifático y que puede estar fusionado con un sistema cíclico mono o policíclico saturado o insaturado, no sustituido o al menos monosustituido y/o puede enlazarse por un grupo alquileno C1-6 lineal o ramificado, no sustituido o al menos monosustituido; o representa un radical arilo o heteroarilo de 5 a 14 miembros no sustituido o al menos monosustituido que puede estar fusionado con un sistema cíclico mono- o policíclico saturado o insaturado, no sustituido o al menos monosustituido y/o se puede enlazar por un grupo alquileno C1- 6- lineal o ramificado, no sustituido o al menos monosustituido; R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R27, R28 y R29, independientemente entre sí, cada uno representa un radical alifático C1-10 lineal o ramificado, saturado o insaturado, no sustituido o al menos monosustituido; representa un radical cicloalifático de 3, 4, 5, 6, 7, 8, o 9 miembros insaturado o saturado, no sustituido o al menos monosustituido, opcionalmente comprendiendo al menos un heteroátomo como miembro del anillo, en lo cual el radical puede fusionarse con un sistema cíclico mono o policíclico saturado o insaturado, no sustituido o al menos monosustituido y/o se puede enlazar por un grupo alquileno C1-6- o un grupo heteroalquileno de 2 a 6 miembros lineal o ramificado, no sustituido o al menos monosustituido; o representa un radical arilo o heteroarilo de 5 hasta 14 miembros no sustituido o al menos monosustituido que puede estar fusionado con un sistema cíclico mono o policíclico saturado o insaturado, no sustituido o al menos monosustituido y/o se puede enlazar por un grupo alquileno .C1-6- o un grupo heteroalquileno de 2 a 6 miembros lineal o ramificado. no sustituido o al menos monosustituido; o R12 y R13 cada uno juntos forman, con el átomo de nitrogeno como miembro del anillo que los enlaza, un radical heterocicloalifático de 4, 5, 6, 7, 8 o 9 miembros saturado o insaturado, no sustituido o al menos monosustituido, que comprende opcionalmente al menos otro heteroátomo como miembro del anillo, que puede estar fusionado con un sistema cíclico mono o policíclico saturado o insaturado, no sustituido o al menos monosustituido; y R25 y R26, independientemente entre sí, cada uno representa un radical hidrogeno; representa un radical alifático C1-10 lineal o ramificado, saturado o insaturado, no sustituido o al menos monosustituido; representa un radical arilo o heteroarilo de 5 a 14 miembros no sustituido o al menos monosustituido, que puede estar fusionado con un sistema cíclico mono o policíclico saturado o insaturado, no sustituido o al menos monosustituido y/o se puede enlazar por un grupo alquileno C1-6 o un grupo alquenileno C2-6 o un grupo alquinileno C2- 6- lineal o ramificado, no sustituido o al menos monosustituido; o representa un radical cicloalifático de 3, 4, 5, 6, 7, 8, o 9 miembros insaturado o saturado, no sustituido o al menos monosustituido, que presenta opcionalmente al menos un heteroátomo como miembro del anillo; con la condicion que R25 y R26 no representan cada uno un radical hidrogeno; o R25 y R26 cada uno juntos forman, con el átomo de carbono como miembro del anillo que los enlaza, un radical cicloalifático de 3, 4, 5 o 6 miembros saturado o insaturado, no sustituido o al menos monosustituido; y R30, R31 y R32, independientemente entre sí, cada uno representa un radical alifático C1-10 lineal o ramificado, saturado o insaturado, no sustituido o al menos monosustituido; cada uno opcionalmente en forma de uno de sus estereoisomeros puros, en particular enantiomeros o diaestereoisomeros, de sus racematos o en forma de una mezcla de estereoisomeros, en particular de los enantiomeros y/o diaestereomeros en cualquier proporcion de mezcla, o cada uno en forma de sales correspondientes o cada uno en forma de solvatos correspondientes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72785905P | 2005-10-19 | 2005-10-19 | |
DE200510050408 DE102005050408A1 (de) | 2005-10-19 | 2005-10-19 | Neue Vanilloidrezeptor-Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
DE102005055486 | 2005-11-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR056875A1 true AR056875A1 (es) | 2007-10-31 |
Family
ID=45220166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060104575A AR056875A1 (es) | 2005-10-19 | 2006-10-19 | Ligandos del receptor vaniloide y su aplicacion para la fabricacion de medicamentos |
Country Status (20)
Country | Link |
---|---|
US (2) | US8710233B2 (es) |
EP (2) | EP1940821B1 (es) |
JP (1) | JP5323485B2 (es) |
KR (1) | KR101347102B1 (es) |
CN (2) | CN101331124B (es) |
AR (1) | AR056875A1 (es) |
AU (2) | AU2006303437B2 (es) |
BR (1) | BRPI0618417A2 (es) |
CA (1) | CA2625189A1 (es) |
DK (1) | DK1940821T3 (es) |
ES (1) | ES2416336T3 (es) |
HR (1) | HRP20130454T1 (es) |
IL (2) | IL190654A (es) |
NO (1) | NO20082160L (es) |
NZ (2) | NZ593684A (es) |
PE (2) | PE20070528A1 (es) |
PL (1) | PL1940821T3 (es) |
PT (1) | PT1940821E (es) |
SI (1) | SI1940821T1 (es) |
WO (1) | WO2007045462A2 (es) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
PT1940821E (pt) | 2005-10-19 | 2013-05-29 | Gruenenthal Gmbh | Novos ligandos do receptor de vanilóide e seu uso para a produção de medicamentos |
SI1945632T1 (sl) | 2005-11-08 | 2014-03-31 | Vertex Pharmaceuticals Incorporated | Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto |
DE102007018150A1 (de) * | 2007-04-16 | 2008-10-23 | Grünenthal GmbH | VR1-Rezeptor-Liganden und µ-Opioid-Rezeptor-Liganden zur Behandlung von Schmerz |
US20080153845A1 (en) * | 2006-10-27 | 2008-06-26 | Redpoint Bio Corporation | Trpv1 antagonists and uses thereof |
US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
WO2008110351A2 (en) * | 2007-03-15 | 2008-09-18 | Dompe' Pha.R.Ma S.P.A. | Use of (r) and (s)-2-aryl-propionic acid derivatives as antiseptic agents |
WO2008125295A2 (de) * | 2007-04-13 | 2008-10-23 | Grünenthal GmbH | Neue vanilloid-rezeptor liganden und ihre verwendung zur herstellung von arzneimitteln |
DE102007017884A1 (de) | 2007-04-13 | 2008-10-16 | Grünethal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
DE102007018151A1 (de) * | 2007-04-16 | 2008-10-23 | Günenthal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
CA2686838C (en) | 2007-05-09 | 2017-03-14 | Vertex Pharmaceuticals Incorporated | Modulators of cftr |
UA102534C2 (en) | 2007-12-07 | 2013-07-25 | Вертекс Фармасьютикалз Инкорпорейтед | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]-dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
PL2231606T3 (pl) | 2007-12-07 | 2013-07-31 | Vertex Pharma | Sposoby wytwarzania kwasów cykloalkilokarboksyamidopirydynobenzoesowych |
CN101925575B (zh) | 2008-01-28 | 2014-06-18 | 株式会社爱茉莉太平洋 | 作为香草酸受体拮抗剂的化合物、其异构体或其药物学可接受的盐、及包含这些化合物的药物组合物 |
CA2716109C (en) | 2008-02-28 | 2016-07-19 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
LT2273983T (lt) | 2008-05-09 | 2016-10-25 | Grünenthal GmbH | Tarpinės miltelių kompozicijos gamybos būdas ir galutinė kieta dozavimo forma naudojant purškalo kietinimo stadija |
CN102137851B (zh) * | 2008-07-02 | 2014-08-27 | 株式会社爱茉莉太平洋 | 作为香草素受体拮抗剂的化合物、其异构体或其药学可接受的盐以及包含它们的药物组合物 |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
US8946204B2 (en) | 2009-05-07 | 2015-02-03 | Gruenenthal Gmbh | Substituted phenylureas and phenylamides as vanilloid receptor ligands |
ES2640257T3 (es) * | 2009-05-07 | 2017-11-02 | Medifron Dbt Inc. | Fenilureas y fenilamidas sustituidas como ligandos del receptor vanilloide |
JP2012529535A (ja) | 2009-06-12 | 2012-11-22 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼモジュレーターとして有用なニコチンアミド化合物 |
WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
JP2013518085A (ja) | 2010-02-01 | 2013-05-20 | ノバルティス アーゲー | CRF−1受容体アンタゴニストとしてのピラゾロ[5,1b]オキサゾール誘導体 |
WO2011095450A1 (en) | 2010-02-02 | 2011-08-11 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
CN106943403A (zh) | 2010-04-07 | 2017-07-14 | 弗特克斯药品有限公司 | 药物组合物和其给药方法 |
US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
WO2011160206A1 (en) | 2010-06-23 | 2011-12-29 | Morin Ryan D | Biomarkers for non-hodgkin lymphomas and uses thereof |
US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
CA3176977A1 (en) | 2010-09-10 | 2012-03-15 | Epizyme, Inc. | Inhibitors of human ezh2, and methods of use thereof |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
WO2013013817A1 (en) | 2011-07-26 | 2013-01-31 | Grünenthal GmbH | Substituted heterocyclic aza derivatives |
CA2842976A1 (en) | 2011-07-26 | 2013-01-31 | Grunenthal Gmbh | Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands |
SI2736495T1 (sl) | 2011-07-29 | 2017-12-29 | Gruenenthal Gmbh | Tableta, odporna proti zlorabi, ki zagotavlja takojšnje sproščanje zdravila |
BR112014006675A2 (pt) * | 2011-09-26 | 2017-04-04 | Gruenenthal Gmbh | derivados de metanossulfonamida substituídos como ligantes de receptor vaniloide |
CA2849960A1 (en) * | 2011-09-26 | 2013-04-04 | Grunenthal Gmbh | Aryl or n-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands |
CA2849350A1 (en) * | 2011-09-26 | 2013-04-04 | Grunenthal Gmbh | Amine substituted methanesulfonamide derivatives as vanilloid receptor ligands |
WO2013068462A1 (en) * | 2011-11-09 | 2013-05-16 | Grünenthal GmbH | Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an n-containing group as vanilloid receptor ligands |
TW201326133A (zh) * | 2011-11-09 | 2013-07-01 | Gruenenthal Gmbh | 以被取代吡唑基甲醯胺及被以一含氧基團取代之含有一苯基基元之尿素衍生物做為類香草素受體之配位體 |
IL282732B2 (en) | 2012-04-13 | 2023-04-01 | Eisai R&D Man Co Ltd | Salt form of human histone methyltransferase inhibitor 2ezh |
WO2014028829A1 (en) | 2012-08-16 | 2014-02-20 | The Scripps Research Institute | Novel kappa opioid ligands |
CN110041250A (zh) | 2012-10-15 | 2019-07-23 | Epizyme股份有限公司 | 经取代的苯化合物 |
MA38949A1 (fr) | 2013-10-16 | 2017-07-31 | Eisai R&D Man Co Ltd | Forme saline d'hydrochlorure pour inhibition d'ezh2 |
CN105848657B (zh) | 2013-11-12 | 2020-05-22 | 沃泰克斯药物股份有限公司 | 制备用于治疗cftr介导的疾病的药物组合物的方法 |
EP3221692B1 (en) | 2014-11-18 | 2021-06-23 | Vertex Pharmaceuticals Inc. | Process of conducting high throughput testing high performance liquid chromatography |
MY193423A (en) | 2015-11-16 | 2022-10-12 | Esteve Labor Dr | Oxadiazaspiro compounds for the treatment of drug abuse and addiction |
US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
PL3464272T3 (pl) | 2016-06-07 | 2022-03-28 | Jacobio Pharmaceuticals Co., Ltd. | Nowe pochodne heterocykliczne użyteczne jako inhibitory SHP2 |
WO2018112843A1 (en) * | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
TWI664175B (zh) | 2017-03-23 | 2019-07-01 | 大陸商北京加科思新藥研發有限公司 | 用於作為shp2抑制劑之新穎雜環衍生物 |
MA53002A (fr) | 2018-06-27 | 2021-05-05 | Eth Zuerich | Nouveaux composés de pyridine et de pyrazine en tant qu'inhibiteurs du récepteur cannabinoïde 2 |
WO2020002314A1 (en) | 2018-06-27 | 2020-01-02 | F. Hoffmann-La Roche Ag | Radiolabeled cannabinoid receptor 2 ligand |
AU2019344899A1 (en) | 2018-09-18 | 2021-04-15 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as Src homology-2 phosphatase inhibitors |
RU2755206C1 (ru) | 2020-05-20 | 2021-09-14 | Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) | Средство пролонгированного анальгетического действия и лекарственный препарат на его основе |
TW202214574A (zh) * | 2020-06-08 | 2022-04-16 | 加拿大商愛彼特生物製藥公司 | 經取代之(呔-1-基甲基)脲類、經取代之n-(呔-1-基甲基)醯胺類及其類似物 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1209016C (zh) * | 1999-08-18 | 2005-07-06 | 阿方蒂农科有限公司 | 杀真菌剂 |
ATE240284T1 (de) * | 2000-03-06 | 2003-05-15 | Solvias Ag | Organische verbindungen durch kopplung von nukleophilen, vinylverbindungen oder co mit wasser, alkohole oder aminen |
CN100439332C (zh) * | 2000-08-21 | 2008-12-03 | 株式会社太平洋 | 硫脲衍生物以及包含该衍生物的药物组合物 |
WO2002016319A1 (en) * | 2000-08-21 | 2002-02-28 | Pacific Corporation | Novel thiourea compounds and the pharmaceutical compositions containing the same |
US7915264B2 (en) * | 2001-03-26 | 2011-03-29 | Novartis Ag | Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain |
KR100707123B1 (ko) | 2003-07-02 | 2007-04-16 | 그뤼넨탈 게엠베하 | 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 4-(메틸설포닐아미노)페닐 동족체 및 이를함유하는 약학적 조성물 |
JP5197016B2 (ja) | 2004-12-23 | 2013-05-15 | デシファラ ファーマスーティカルズ, エルエルシー | 酵素モジュレータ及び治療 |
US7888374B2 (en) | 2005-01-28 | 2011-02-15 | Abbott Laboratories | Inhibitors of c-jun N-terminal kinases |
US7572808B2 (en) * | 2005-06-17 | 2009-08-11 | Bristol-Myers Squibb Company | Triazolopyridine cannabinoid receptor 1 antagonists |
PT1940821E (pt) | 2005-10-19 | 2013-05-29 | Gruenenthal Gmbh | Novos ligandos do receptor de vanilóide e seu uso para a produção de medicamentos |
-
2006
- 2006-10-19 PT PT68063726T patent/PT1940821E/pt unknown
- 2006-10-19 PL PL06806372T patent/PL1940821T3/pl unknown
- 2006-10-19 PE PE2006001265A patent/PE20070528A1/es not_active Application Discontinuation
- 2006-10-19 NZ NZ593684A patent/NZ593684A/xx not_active IP Right Cessation
- 2006-10-19 AR ARP060104575A patent/AR056875A1/es unknown
- 2006-10-19 AU AU2006303437A patent/AU2006303437B2/en not_active Ceased
- 2006-10-19 SI SI200631590T patent/SI1940821T1/sl unknown
- 2006-10-19 US US11/551,060 patent/US8710233B2/en not_active Expired - Fee Related
- 2006-10-19 WO PCT/EP2006/010057 patent/WO2007045462A2/de active Application Filing
- 2006-10-19 KR KR1020087011879A patent/KR101347102B1/ko not_active IP Right Cessation
- 2006-10-19 DK DK06806372.6T patent/DK1940821T3/da active
- 2006-10-19 CA CA002625189A patent/CA2625189A1/en not_active Abandoned
- 2006-10-19 CN CN200680047690XA patent/CN101331124B/zh not_active Expired - Fee Related
- 2006-10-19 PE PE2011000141A patent/PE20110285A1/es not_active Application Discontinuation
- 2006-10-19 JP JP2008535966A patent/JP5323485B2/ja not_active Expired - Fee Related
- 2006-10-19 CN CN2013101402854A patent/CN103382176A/zh active Pending
- 2006-10-19 NZ NZ567936A patent/NZ567936A/en not_active IP Right Cessation
- 2006-10-19 EP EP06806372A patent/EP1940821B1/de active Active
- 2006-10-19 EP EP11006751A patent/EP2388258A1/de not_active Withdrawn
- 2006-10-19 BR BRPI0618417-0A patent/BRPI0618417A2/pt not_active IP Right Cessation
- 2006-10-19 ES ES06806372T patent/ES2416336T3/es active Active
-
2008
- 2008-04-07 IL IL190654A patent/IL190654A/en not_active IP Right Cessation
- 2008-05-08 NO NO20082160A patent/NO20082160L/no not_active Application Discontinuation
-
2012
- 2012-04-24 IL IL219380A patent/IL219380A/en not_active IP Right Cessation
- 2012-05-29 AU AU2012203162A patent/AU2012203162A1/en not_active Abandoned
-
2013
- 2013-05-24 HR HRP20130454TT patent/HRP20130454T1/hr unknown
-
2014
- 2014-02-25 US US14/190,007 patent/US20140179686A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR056875A1 (es) | Ligandos del receptor vaniloide y su aplicacion para la fabricacion de medicamentos | |
AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
AR073138A1 (es) | Derivados de dioxa-biciclo (3.2.1) octano- 2,3,4-triol | |
AR047966A1 (es) | Compuestos poliheterociclicos y su uso como antagonistas del receptor de glutamato metabotropico | |
AR061739A1 (es) | Nuevos derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
AR056511A1 (es) | Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4 | |
AR078152A1 (es) | Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden | |
AR045388A1 (es) | Inhibidores del c-kit imidazopiridinicos n3-sustituidos | |
AR058073A1 (es) | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos | |
AR083070A1 (es) | Analogos de nucleotidos sustituidos con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales, en particular infecciones por vhc | |
AR091790A1 (es) | Derivados de isoquinolin-1-ona y sus usos | |
ECSP055853A (es) | Nuevos derivados de fluoroglicosidos heterociclicos, productos farmaceuticos que contienen dichos compuestos, y el uso de los mismos | |
AR079553A1 (es) | Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros. | |
CY1114906T1 (el) | Νεα παραγωγα 6-τριαζολοπυριδαζινο-σουλφανυλο βενζοθειαζολης και βενζιμιδαζολης, η διαδικασια της παρασκευης τους, η εφαρμογη τους ως φαρμακα, φαρμακευτικες συνθεσεις και νεα χρηση κυριως ως αναστολεις του μετ | |
PE20060570A1 (es) | Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10 | |
AR057987A1 (es) | Compuestos agonistas de cb1 (receptor cannabinoide) | |
UY29702A1 (es) | Inhibidores macrocíclicos del virus de hepatitis c | |
AR052659A1 (es) | Derivados de purina agonistas del receptor de adenosina a2a | |
AR089774A1 (es) | Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
GT200700036A (es) | Compuestos fenil amido heterociclicos condensados | |
AR038240A1 (es) | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion | |
AR020165A1 (es) | Derivados de pirimidinas sustituidas, su procedimiento de preparacion, composiciones farmaceuticas que las contienen y el uso de los mismos para la preparacion de medicamentos | |
AR035858A1 (es) | Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3 | |
AR044342A1 (es) | Derivados de bencimidazol | |
AR045155A1 (es) | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |